Signal transducer and activator of transcription-5 (Stat5) mediates prolactin (PRL)-induced differentiation and growth of breast epithelial cells. We have recently identified active Stat5 as a tumor marker of favorable prognosis in human breast cancer, and determined that Stat5 activation is lost during metastatic progression. Here we provide novel evidence for an invasion-suppressive role of Stat5 in human breast cancer. Activation of Stat5 by PRL in human breast cancer lines was associated with increased surface levels of the invasion-suppressive adhesion molecule E-cadherin in vitro and in xenotransplant tumors in vivo. Inducible E-cadherin was blocked by dominant-negative (Dn) Stat5 or Dn-Jak2, but not by Dn-Stat3. Further experimental data indicated a role of Stat5 as a coordinate regulator of additional invasion-related characteristics of human breast cancer cells, including cell surface association of b-catenin, homotypic cell clustering, invasion through Matrigel, cell migration, and matrix metalloproteinase activity. A role of Stat5 as a suppressor of breast cancer invasion and metastatic progression provides a biological mechanism to explain the favorable prognosis associated with active Stat5 in human breast cancer.
Introduction
Signal transducer and activator of transcription-5 (Stat5) was originally identified as a prolactin (PRL) activated mammary gland transcription factor . A highly homologous Stat5b gene was also identified and was found to be expressed in the mammary gland (Liu et al., 1995) . Stat5a and Stat5b are activated by phosphorylation of a conserved tyrosine residue, which in turn facilitates homo-or heterodimerization, nuclear translocation, and binding of Stat5 to specific DNA response elements . Genetic studies have revealed that Stat5a and Stat5b mediate PRL-induced mouse mammary gland development (Liu et al., 1997; Udy et al., 1997) . Specifically, Stat5a and Stat5b control growth and differentiation of the secretory alveolar cell compartment during pregnancy and lactation. While lactation is suppressed relatively more by genetic loss of Stat5a than Stat5b, Stat5b is still capable of compensating for loss of Stat5a so that lactation is restored in Stat5a null mice after multiple pregnancies (Liu et al., 1998; Nevalainen et al., 2002) . Thus, the highly homologous Stat5a and Stat5b both promote mammary gland differentiation and development, despite the existence of subtle and possibly important differences in their structure and regulation (Grimley et al., 1999; Kabotyanski and Rosen, 2003) .
Initial investigations have indicated a mammary tumor-promoting role of Stat5 in mice, which is consistent with the established mammary tumor-promoting role of PRL in rodents (Clevenger et al., 2003) . Mammary tumorigenesis was delayed when the Stat5a gene was deleted in transgenic mice with mammarydirected expression of transforming growth factor-a (TGFa) or SV40 large-T antigen (Humphreys and Hennighausen, 1999; Ren et al., 2002) . In addition, transgenic overexpression of a constitutively active Stat5-Jak2 chimeric protein in the mouse mammary gland was associated with increased predisposition for mammary tumors (Iavnilovitch et al., 2002) . A cellular survival role of Stat5 has been described in preneoplastic and malignant mouse mammary epithelia (Humphreys and Hennighausen, 1999; Miyoshi et al., 2001; Ren et al., 2002) , providing a possible mechanism for how Stat5 may promote mammary tumorigenesis in mice.
In human breast cancer, on the other hand, we have recently reported a favorable prognosis in patients whose tumors display active Stat5 (Nevalainen et al., 2004) . Our observations were based on detection of nuclear-localized, tyrosine-phosphorylated Stat5 in tumors of two independent clinical materials totaling more than 1000 patients. Active Stat5 in tumors specifically predicted reduced risk of both disease recurrence and death from breast cancer, particularly in early-stage cancer before lymph node metastases were detectable. This prognostic value of Stat5 was independent of age, tumor size, histological grade, Her2/neu, and estrogen/ progesterone receptor status (Nevalainen et al., 2004) . Importantly, using the same phospho-Stat5 immunohistochemistry method, we have reported constitutive basal activation of Stat5 in healthy, nonpregnant human breast epithelia and found that inactivation or loss of Stat5 in human breast cancer correlated with metastatic progression (Nevalainen et al., 2004) . In parallel work, human breast cancer histological differentiation was positively correlated with nuclear levels of Stat5 protein (Cotarla et al., 2004) , as well as with nuclear levels of tyrosine-phosphorylated Stat5 (Nevalainen and Rui, in preparation) .
Based on the new data on Stat5 activation in normal and malignant human breast, we hypothesized that the central role of Stat5 as a normal breast epithelial differentiation factor is maintained in early breast cancer, and that the favorable prognosis associated with active Stat5 is a result of inhibition by Stat5 of metastatic dispersal of cells from the primary tumor. We now report novel evidence for an invasion-suppressive role of Stat5 in human breast cancer cells. From studies of well-differentiated, estrogen receptor (ER)-positive T-47D and ZR-75-1 cells, and poorly differentiated, ER-negative BT-20 cells, systematic activation or inactivation of Stat5 revealed a broad role of Stat5 as a stimulator of homotypic cell clustering and cell surface accumulation of E-cadherin and surface-associated b-catenin. Moreover, Stat5 suppressed invasive features such as cell scattering, matrix metalloproteinase (MMP) secretion, cell invasion through Matrigel, and cell migration. Collectively, the observations support a novel role of Stat5 as a suppressor of breast cancer cell dispersal and metastatic progression, and provide a biological link between Stat5 activation and favorable prognosis in human breast cancer.
Results

Activation of Stat5 is associated with increased stability of cell surface E-cadherin in human breast cancer cell lines in vitro
To detect cell surface E-cadherin, cell surface proteins were first biotinylated and E-cadherin was subsequently immunoprecipitated from cell lysates using anti-Ecadherin antibodies, followed by detection of 120 kDa biotinylated E-cadherin by streptavidin-conjugated horseradish peroxidase. In parallel, whole-cell E-cadherin levels were analysed by Western blotting with specific E-cadherin antibody. In human breast cancer cell lines T-47D and ZR-75-1, but not BT-20, treatment with 20 nM PRL led to a marked accumulation of E-cadherin on the cell surface within 12-24 h ( Figure 1A ). Based on three experiments, reblotting with E-cadherin antibodies indicated that the overall cellular protein levels of E-cadherin did not change markedly in either of the three cell lines under the in vitro conditions used. Furthermore, N-cadherin or P-cadherin was not detected in either cell line, except for P-cadherin expression in BT-20 cells (data not shown).
Importantly, the ability of PRL to elevate cell surface E-cadherin levels in the three cell lines correlated with the ability of PRL to activate Stat5. In parallel experiments, PRL-inducible phosphorylation of Stat5a and Stat5b was determined in cells treated with or without 20 nM PRL for 15 min and analysed by Western blotting of Stat5a or Stat5b immunoprecipitated from whole-cell lysates using a specific anti-phospho-Stat5a/b (Tyr694/9) antibody. These experiments demonstrated that in T-47D and ZR-75-1 cells PRL induced rapid tyrosine phosphorylation of both Stat5a and Stat5b, while in BT-20 cells no detectable activation of either Stat5a or Stat5b was observed ( Figure 1B) . Taken together, these data supported the notion that Stat5 activation was associated with enhanced levels of E-cadherin on the surface of breast cancer cells.
Activation of Stat5 is associated with increased E-cadherin levels in human T-47D breast cancer xenotransplants in vivo
To determine whether PRL-induced Stat5 activation would lead to elevated E-cadherin levels in established T-47D xenotransplant tumors in nude mice, we injected tumor-bearing mice once daily with PRL for up to 4 days. Stat5 was not active in T-47D tumors when grown in nude mice as revealed by immunohistochemistry of active Stat5 in paraffin-embedded, formalin-fixed tumors, despite exposure to normal circulating levels of mouse PRL ( Figure 1C, panel a) . However, in response to injected human PRL, Stat5 became activated as detected by nuclear localization of tyrosine-phosphorylated Stat5 in tumors of PRL-treated animals at days 2 and 4 ( Figure 1C , panels b and c). We then analysed E-cadherin levels in the tumors by immunohistochemistry and immunoblotting.
Immunohistochemistry for E-cadherin on sections of formalin-fixed, paraffin-embedded tumor tissues revealed that E-cadherin levels were low in untreated tumors, but were readily upregulated at the cellular junctions after 2 and 4 days of PRL treatment ( Figure 1C , panels d-f). Independently, we determined total levels of E-cadherin in tumor homogenates by Western blotting. Clarified homogenates from frozen tumors from three mice in each treatment group were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (20 mg/lane) and immunoblotted with antibodies to either E-cadherin or b-actin. Little or no E-cadherin was detectable in untreated tumors, while there was a time-dependent increase in the levels of E-cadherin in the tumors during 4 days of PRL treatment ( Figure 1D ). In contrast, levels of b-actin remained constant. We conclude that treatment of nude mice carrying T-47D tumors with PRL led to activation of Stat5 in the tumors and increased levels of the homotypic adhesion molecule E-cadherin.
Dn-Stat5, but not Dn-Stat3, disrupts PRL-induced E-cadherin stabilization on the surface of human T-47D breast cancer cells Because we and others have reported that PRL activates other intracellular intermediaries in addition to Stat5 in T-47D cells, including Stat3 and the Ras-MAPK pathway (Erwin et al., 1995; Das and Vonderhaar, 1996; Schaber et al., 1998) , we proceeded to test whether the mechanism of PRL-enhanced elevation of surface E-cadherin in T-47D cells required Stat5 activation. For these studies, we generated adenoviral gene vectors for high-efficiency delivery of dominant-negative (Dn) and wild type (Wt) Stat5a and Stat3. Because the C-terminal truncation mutant Stat5aD713 acts as a Dn for both Stat5a and Stat5b, we hereafter refer to this mutant as Dn-Stat5. T-47D breast cancer cells were incubated with or without PRL for 18 h after gene delivery of either In epithelial cells, intracellular b-catenin typically associates with the cytoplasmic domain of E-cadherin when E-cadherin accumulates at the cell membrane.
Upregulation of E-cadherin sequesters b-catenin from the cytoplasm and thereby prevents b-catenin from translocating to the nucleus where it may act as a transcriptional regulator (Stockinger et al., 2001) . The localization of b-catenin and E-cadherin as a complex at cell-cell adherens junctions is necessary for proper epithelial cell function and tissue integrity (Kemler and Ozawa, 1989) , and this protein complex plays a key role in suppression of metastatic tumor progression (Mbalaviele et al., 1996) . To determine whether PRL-induced stabilization of E-cadherin on the cell surface of T-47D cells also was associated with b-catenin localization at the cell surface, cellular b-catenin localization was analysed by immunofluorescence staining. 
PRL treatment of T-47D cells is associated with inhibition of EGF-induced tyrosine phosphorylation of b-catenin
Tyrosine phosphorylation of b-catenin has been reported to promote metastatic progression of tumor cells (Kinch et al., 1995) . Since EGF treatment is an established method for stimulating the tyrosine phosphorylation of b-catenin, T-47D cells were treated with 8 nM EGF for 30 min after activation of Stat5 by 20 nM PRL for different time intervals and were subjected to Western blot analysis. As shown in Figure 3b , there was a significant decrease in EGF-induced tyrosine phosphorylation of b-catenin at 18 h of PRL treatment, corresponding temporally with maximal enhancement of surface E-cadherin levels. Furthermore, EGF receptor autophosphorylation and expression levels remained constant throughout the experiment ( Figure 3c ). Taken together, Stat5 activation may not only enhance E-cadherin/b-catenin complex formation at cell-cell junctions in T-47D cells, but could also help stabilize the b-catenin protein by preventing its tyrosine phosphorylation.
PRL-enhanced upregulation of surface E-cadherin in T-47D cells requires the Stat5 tyrosine kinase Jak2
The tyrosine kinase Jak2 is generally considered as the mediator of PRL-induced tyrosine phosphorylation and Representative data from three independent experiments are shown
Stat5 inhibits breast cancer cell invasion AS Sultan et al activation of Stat5 in breast epithelia (Wagner et al., 2004) . We therefore predicted that blocking Jak2 activation would disrupt PRL-induced upregulation of E-cadherin at cellular junctions in T-47D cells. For these studies, T-47D cells were exposed to control virus or adenovirus carrying either Dn-Jak2 or Wt-Jak2 and treated with or without PRL for 18 h. PRL enhanced E-cadherin staining intensity at cell junctions (Figure 4a and b) and this effect was blocked by Dn-Jak2 ( Figure  4c and d), indicating that PRL enhancement of E-cadherin depended on Jak2 activation. Consistent with this notion, overexpression of Wt-Jak2, which becomes autoactivated at elevated cellular concentrations, was associated with elevated E-cadherin levels in T-47D cells even in the absence of PRL and did not block PRLinduced E-cadherin (Figure 4e and f). Taken together, our data demonstrated that the Stat5 tyrosine kinase Jak2 is critical for PRL induction of E-cadherin in T-47D cells.
Stat5-dependent homotypic clustering of T-47D breast cancer cells on Matrigel
Reduced expression of E-cadherin in breast carcinomas is associated with increased risk of tumor invasion and metastasis as well as unfavorable prognosis (Berx and Van Roy, 2001 ). To investigate the role of Stat5 in the invasive capacity of human breast cancer cells, we examined the role of Stat5 in homotypic cluster formation of T-47D cancer cells cultured on Matrigel, a collagen-rich extracellular matrix that provides a more physiological growth environment than plastic. T-47D cells cultured on Matrigel and treated with PRL showed significant morphological changes with formation of large cell clusters within 24 h as revealed by phase contrast stereomicroscopy (Figure 5a and b) . PRLinduced cell clustering, as well as basal levels of cluster formation observed in control cells, was essentially eliminated in cells overexpressing Dn-Stat5, and the cells were instead highly scattered (Figure 5c Figure 6A , panels e and f). On the other hand, overexpression of Jak2 was associated with a modest but consistent induction of small cell clusters, especially in PRL-treated cells, an effect possibly mediated by activation of low levels of endogenous Stat5 ( Figure 6A , panels g and h). Coexpression of both Wt-Stat5a and Wt-Jak2 markedly stimulated clustering of BT-20 cells on Matrigel ( Figure 6A , panels i and j). The large clusters formed in response to Jak2 and Stat5 were reminiscent of alveolar-like structures, or mammospheres, that are induced by PRL-Jak2-Stat5 signaling in well-differentiated mammary epithelial cell lines such as Comma-D and HC-11 cells (Schmidhauser et al., 1992; Xie et al., 2002) . This notion was supported by the appearance of collapsed domes in the fixed, dehydrated cell cultures ( Figure 6A , panels i and j).
In parallel experiments using the same experimental conditions, we investigated whether inducible clustering of BT-20 cells on Matrigel was associated with increased cellular E-cadherin levels. Western blot analysis on whole-cell lysates showed elevated levels of E-cadherin under conditions where clustering occurred, with highest levels in BT-20 cells overexpressing Wt-Jak2 plus WtStat5a, and lowest levels in control cells and cells expressing Dn-Stat5 ( Figure 6B ). In contrast, cellular bactin levels remained unchanged. Immunohistochemistry of E-cadherin in sections of formalin-fixed, paraffinembedded cellular clusters from Wt-Jak2 plus WtStat5a-expressing cells revealed that E-cadherin was localized to the cellular junctions ( Figure 6C , upper panels). While PRL treatment did not further elevate total E-cadherin levels, PRL-treated spheroids showed frequent evidence of central lumen formation and tended to be larger ( Figure 6C , right panels). Based on these observations, we conclude that reconstitution of an activated Jak2-Stat5 pathway in poorly differentiated BT-20 breast cancer cells enhances E-cadherin levels, homotypic adhesion, and cell clustering.
Activation of Stat5a is associated with reduced invasion and migration of T-47D and BT-20 human breast cancer cell lines
The effect of PRL-activated Stat5a on the invasive potential of T-47D and BT-20 breast cancer cells was next assessed in vitro by invasion and mobility assays. The ability of T-47D and BT-20 cells to invade through Matrigel-coated porous filters in response to a chemotactic stimulus was examined in an 8 mm pore size Boyden chamber assay. Similarly, we tested the ability T-47D and BT-20 cells to migrate through uncoated porous filters. Invasion of T-47D and BT-20 through Matrigel-coated filters was modulated by Stat5 activation. Specifically, T-47D cell invasion was inhibited by approximately 38% by PRL treatment, an effect that was blocked by adenoviral overexpression of Dn-Stat5 (Figure 7b-d) . Furthermore, overexpression of WtStat5a was associated with highly reduced invasion in both untreated and PRL-treated T-47D cells, with as much as 67% inhibition when compared to mockinfected control cells (Figure 7e and f) . In parallel experiments, BT-20 cells showed high basal invasion through Matrigel, and PRL alone did not inhibit invasion unless Wt-Stat5a was introduced into the cells (Figure 7g, h, k, and l) . Dn-Stat5 did not further enhance invasion of BT-20 cells through Matrigel (Figure 7i and j) .
Correspondingly, similar effects of Stat5 were detected in the migration assay through uncoated filters. T-47D cell migration was moderately inhibited by approximately 37% by PRL (Figure 8b ). This PRLinduced inhibition was reversed by adenoviral delivery of Dn-Stat5 to levels that were almost twofold higher than that of PRL-treated control cells (Figure 8c and d) . Furthermore, overexpression of Wt-Stat5a was associated with an approximately 41 and 63% inhibition of migration in untreated and PRL-treated T-47D cells, respectively, when compared to mock-treated cells (Figure 8e and f) . Parallel experiments on BT-20 cells revealed that PRL alone did not inhibit migration, but that Dn-Stat5 in the presence of PRL moderately elevated the migration of BT-20 cells through the filters (Figure 8h-j) . Furthermore, overexpression of WtStat5a in the absence and presence of PRL was associated with approximately 35-48% inhibition (Figure 8k and l) . Collectively, the observations on cell invasion and migration of T-47D and BT-20 cells were highly consistent with the effects on homotypic adhesion and cell clustering and provided further evidence that Stat5 inhibits the invasive phenotype of breast cancer cells.
Stat5a inhibits MMP activity in T-47D and BT-20 human breast cancer cell lines
We further examined whether the Stat5-dependent modulation of invasive features of T-47D and BT-20 cells also included levels of MMP activities that are associated with tumor invasiveness (Coussens and Werb, 1996) . MMP activities were measured by a zymography assay in conditioned media from T-47D or BT-20 cells. Conditioned media from the welldifferentiated T-47D cells showed no detectable MMP activities under basal or PRL-stimulated conditions. However, conditioned medium from T-47D cells following overexpression of Dn-Stat5 produced readily detectable gelatinolytic activity corresponding in size to MMP-2. This induction was enhanced by PRL treatment ( Figure 9, upper panel) . In contrast, T-47D cells overexpressing Wt-Stat5a displayed no basal or PRLinducible MMP-2 activity (Figure 9, upper panel) . In conditioned medium from poorly differentiated BT-20 cells, there were barely detectable gelatinolytic bands corresponding to MMP-9 independent of PRL treatment ( Figure 9 , lower panel). However, Wt-Stat5a overexpression in BT-20 cells was associated with reduction in the activity of MMP-9 in PRL-treated cells, whereas Dn-Stat5 overexpression slightly increased activity of MMP-9 (Figure 9, lower panel) . Overall, the coordinated effects of Stat5 on MMP production in T-47D and BT-20 and other parameters of invasion, including invasion through Matrigel, motility, and homotypic adhesion, support the notion that Stat5 may suppress cellular invasion and metastasis in vivo.
Discussion
The present study provides novel evidence for a role of Stat5 as a suppressor of breast cancer cell invasion. Activation of Stat5 promoted homotypic adhesion of breast cancer cells, as evidenced by Stat5-mediated cell clustering and upregulation of cell surface E-cadherin and b-catenin. In parallel, Stat5 activation negatively regulated breast cancer cell invasion, migration, and MMP secretion. Importantly, combinatory gene delivery of the Jak2 tyrosine kinase and Stat5 into poorly differentiated, ER-negative BT-20 cells effectively restored homotypic cell adhesion and promoted cell clustering. The new data on Stat5 as a coordinate suppressor of invasive characteristics of human breast cancer cells provide a biological mechanism to explain our recent clinical observation that activation of Stat5 in human breast cancer is associated with favorable prognosis (Nevalainen et al., 2004) .
We propose that Stat5 acts as a suppressor of invasion and dispersal of breast cancer cells from the primary tumor. This paradigm is novel in light of the breast tumor-promoting role that has been attributed to Stat5 inhibits breast cancer cell invasion AS Sultan et al unexpected since Stat5 may facilitate mesenchymal transition in kidney epithelial cells (Benitah et al., 2003) . However, an invasion-suppressive role of Stat5 is consistent with a series of other experimental observations in normal and malignant breast epithelial cells. First, the data presented in this report provide direct evidence for an invasion-suppressive role of Stat5 in human breast cancer lines. Second, Stat5 is a key regulator of epithelial differentiation in mouse mammary gland (Kazansky et al., 1995; Liu et al., 1996 Liu et al., , 1997 Teglund et al., 1998) , and Stat5 likewise is hyperactivated during terminal differentiation and lactation in human breast . Third, in human breast cancer, activation of Stat5 correlated positively with histological differentiation (Cotarla et al., 2004) . Finally, Stat5 is active in normal human breast epithelia and loss of basal Stat5 activation correlated with metastatic progression of human breast cancer (Nevalainen et al., 2004) . Collectively, the data indicate that Stat5 maintains cellular differentiation, promotes homotypic adhesion, and inhibits cellular invasion of human breast cancer, and suggest that Stat5 activation in tumors could be causally linked to the markedly reduced risk of latent disease in patients with lymph node-negative breast cancer (Nevalainen et al., 2004) . The positive effect of Stat5 on homotypic breast cancer cell clustering was associated with enhanced accumulation of surface E-cadherin and b-catenin, key protein components of intercellular adherens junctions. Compelling evidence exists to indicate that downregulation of E-cadherin expression or function is a critical event in early metastatic progression of most epithelial tumors, including breast cancer (Bukholm et al., 1998; Fearon, 2003; Wheelock and Johnson, 2003) . While E-cadherin protein levels increased in T-47D tumors in nude mice following 2-4 days of Stat5 activation, total cellular E-cadherin protein levels increased less than the Stat5 inhibits breast cancer cell invasion AS Sultan et al marked increase in cell surface-exposed E-cadherin in monolayer culture. The stimulatory effect of Stat5 on breast cancer E-cadherin levels therefore may not simply reflect a direct transcriptional induction of the E-cadherin gene. Increased stabilization of E-cadherin on the cell surface may in part be due to reduced rates of protein turnover (Le et al., 1999; Paterson et al., 2003) . Furthermore, activation of Stat5 was associated with reduced EGF-induced tyrosine phosphorylation of b-catenin, and with enhanced localization of b-catenin at cell-cell contacts in T-47D cells. Increased tyrosine phosphorylation of b-catenin correlates with the disassembly of adherens junctions and decrease of cell-cell adhesion, and occurs during malignant transformation and tumor invasion (Behrens et al., 1996; Papkoff, 1997; Lilien et al., 2002) . Stat5-induced adherens junction formation in breast cancer cells may therefore involve multiple molecular mechanisms. The PRL-induced enhancement of surface E-cadherin levels detected in T-47D cells was blocked by Dn-Stat5 but not by Dn-Stat3. Intriguingly, Wt-Stat3 also blocked PRL-induced enhancement of surface E-cadherin levels, suggesting that Stat5 and Stat3 exert opposing effects on adherens junction formation in breast cancer cells. Future studies will investigate the mechanisms by which Stat5 and Stat3 transcription factors may differentially affect surface E-cadherin levels. The observed opposite effect of Stat5 and Stat3 on cell adhesion may also be of relevance to mammary gland involution at the end of the lactation cycle, a process in which Stat5 maintains the secretory tissue architecture and cell survival, whereas Stat3 facilitates epithelial involution and massive apoptosis (Chapman et al., 1999; Groner and Hennighausen, 2000) .
MMPs may contribute to metastatic dispersal of cancer cells by degrading extracellular matrix and facilitating intravasal growth (Kim et al., 1998) . A very recent study reported that PRL may inhibit MMP expression in T-47D cells (Philips and McFadden, 2004) , an observation that could be mediated through PRLinduced Stat5 activation, which is consistent with the present work on Stat5 as a suppressor of invasive characteristics. In contrast, two previous reports have suggested that PRL may increase invasiveness of T-47D cells based on in vitro studies. In one study, this interpretation was based on reduced adhesion of T-47D cells to the plastic growth support after extended PRL treatment for 6 days (Shiu and Paterson, 1984) . However, this effect may be secondary to PRL-induced homotypic cell-cell adhesion, especially in light of the parallel evidence of PRL-induced differentiation of the T-47D cells in the same cultures. The second study used wound closure assay and a Boyden chamber setup that involved placement of PRL as a chemoattractant in the target compartment (Maus et al., 1999) . The reported positive effects of PRL on T-47D cell migration may be mediated by PRL-induced signals other than Stat5 under the culture conditions used, which included exogenous insulin and hydrocortisone in the medium. For instance, Stat3, mitogen-activated protein kinases (MAPKs), c-Src, or focal adhesion kinase may also be activated by PRL in T-47D cells (Schaber et al., 1998; Acosta et al., 2003) . Specifically, Stat3 and MAPK were found to be involved in interleukin-6-induced migration of breast cancer cells (Arihiro et al., 2000; Badache and Hynes, 2001 ). Furthermore, peptide growth factors and culture conditions may directly affect PRL signaling (Marte et al., 1995; Yamashita et al., 1999) , and contextdependent PRL signaling may contribute to the complex roles of PRL in human breast cancer development and progression (Clevenger et al., 2003) . Finally, in some experimental settings, and especially when T-47D cells were exposed to Matrigel (e.g. Figures 5 and 7) , Stat5 overexpression alone exerted some effect even in the absence of PRL, indicating that Stat5 is activated by other factors under these conditions. In summary, the present study provides novel evidence for a role of Stat5 as a suppressor of human breast cancer invasiveness. This notion is consistent with the significantly reduced risk of disease recurrence in lymph node-negative breast cancer in which Stat5 is active (Nevalainen et al., 2004) . Ongoing work will determine whether Stat5 directly inhibits metastasis formation of human breast cancer in athymic nude mice. Future studies will also identify the mechanisms underlying Stat5-induced upregulation of E-cadherin at cellular junctions in breast epithelial cells. Finally, the restoration of homotypic clustering of the ER-negative BT-20 breast cancer cell line by gene delivery of Jak2 and Stat5 may be explored as a new strategy for metastasis-suppressive differentiation therapy. Manassas, VA, USA) and were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS; GIBCO, Carlsbad, CA, USA), 2 mM Lglutamine, and penicillin/streptomycin (Sigma, St Louis, MO, USA) (50 IU/ml) at 371C with 5% CO 2 . Unless stated otherwise, subconfluent cells in 75 cm 2 flasks were washed with phosphate-buffered saline (PBS) and maintained in DMEM with 2% FBS for 24 h before treatment with or without 20 nM human PRL for 18 h. Cell numbers were determined by a Beckman Coulter Counter (Fullerton, CA, USA).
Materials and methods
Cell culture
Antibodies and reagents
Human PRL (NIDDK-PRL-SIAFP-B2, AFP-2969A) was kindly provided by Dr AF Parlow under the sponsorship of the National Hormone and Pituitary Program, National Institutes of Health (NIH) and the US Department of Agriculture. Mouse monoclonal antibodies against human Ecadherin (G10) and human b-catenin, and rabbit polyclonal antibody against human EGF-R were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). For immunohistochemistry of formalin-fixed, paraffin-embedded tissue, mouse anti-human E-cadherin antibody NCH-38 from DakoCytomation (Carpinteria, CA, USA) was used. Monoclonal anti-phosphotyrosine-Stat5 antibody (AX1) and polyclonal rabbit antisera to Stat5a (AX551) and Stat5b (AX554) were provided by Advantex BioReagents (Conroe, TX, USA), and monoclonal anti-phosphotyrosine antibody 4G10 was from Upstate Biotechnology (Lake Placid, NY, USA). A detection kit (Vectastain ABC) based on horseradish peroxidase-avidin complex and a fluorescent anti-mouse IgG kit were obtained from Vector Laboratories (Burlingame, CA, USA). Protein GSepharose 4FF beads and enhanced chemiluminescence (ECL) reagents were obtained from Amersham Pharmacia Biotech (Piscataway, NJ, USA). The bicinchoninic acid (BCA) kit for protein detection was obtained from Pierce (Rockford, IL, USA).
Generation of adenoviral vectors for high-efficiency gene delivery of Wt and Dn forms of Stat5, Stat3, and Jak2
Expression vector for murine Stat5a (pXM-Stat5a) was kindly provided by Xiuwen Liu and Lothar Hennighausen (NIH, Bethesda, MD, USA). A C-terminally truncated variant of Stat5a (Stat5aD713) that blocks both Stat5a and Stat5b-mediated gene transcription and was derived by deletion after amino-acid residue Ala-713 of pXM-Stat5a was subcloned, in parallel with the matching Wt-Stat5a cDNA, into the pShuttle-CMV transfer vector of the AdEasy adenoviral vector system (Qbiogene, Carlsbad, CA, USA) as described (Ahonen et al., 2003) . To generate a parallel set of reagents for Stat3, fulllength human Stat3 cDNA open reading frame was cloned from a human placenta cDNA library (J Xie and H Rui, unpublished data). Wt-Stat3 cDNA, and a Dn variant of Stat3 (Dn-Stat3D715) derived by truncation of the Wt-Stat3 cDNA by replacing the codon for amino-acid residue Thr-716 with a stop codon were used. Adenoviruses carrying Wt-Jak2 or a kinase domain deleted Dn-Jak2 with C-terminal V5/His epitope tags were derived from rat Jak2 constructs that we have previously described (Duhe et al., 1995; Xie et al., 2002) and were subcloned into the pShuttle-CMV transfer vector of the AdEasy system. In all cases, selected recombinant viral stocks were expanded in large-scale QBI-293A cell cultures (Qbiogene, Carlsbad, CA, USA), purified by double cesium chloride gradient centrifugation, and titered using a standard plaque assay in QBI-293A cells.
Cell surface biotinylation
Cell surface biotinylation was performed as described previously with minor modifications (Sultan et al., 1997) . Briefly, cells were grown to semiconfluence in 75 cm 2 dishes, washed three times with ice-cold PBS, and biotinylated with 0.5 mg/ml sulfo-NHS-LC-Biotin in PBS (Pierce, Rockford, IL, USA) for 30 min on ice. Excess reagent was quenched and removed by washing with ice-cold DMEM containing 10% FBS. Cells were then resuspended in 0.5 ml of the following lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100/1% deoxycholate) containing 1 mM phenylmethylsulfonyl fluoride and 10 mg/ml each of aprotinin, leupeptin, antipain, and pepstatin.
After centrifugation at 15 000 g for 20 min at 41C, equal amounts of protein were immunoprecipitated with 5 mg/ml of monoclonal anti-E-cadherin antibody at 41C overnight, followed by incubation with Protein G-Sepharose 4 FF beads for 1.5 h. Immunoprecipitates were washed five times in lysis buffer, solubilized in SDS electrophoresis sample buffer, separated on a 7% SDS gel, and transferred to a polyvinylidene fluoride membrane (Millipore, Bedford, MA, USA). After blocking the membranes with 3% (w/v) skim milk in Tris-buffered saline containing 0.1% (v/v) Tween 20 (TBST, pH 7.5), the biotinylated proteins were visualized using the Vectastain ABC kit. After five washes of 10 min each with PBS containing 0.05% Tween 20, the membranes were treated with ECL Western blotting detection reagents for 1 min at room temperature and were exposed to BioMax film (Eastman Kodak, Rochester, NY, USA).
Immunoprecipitation and immunoblotting
Monolayers of cells were washed with PBS at room temperature and extracted on ice with 2.5 ml/75 cm 2 flask of the following lysis buffer (10 mM Tris-HCl (pH 7.6), 5 mM EDTA, 150 mM NaCl, 30 mM sodium pyrophosphate, 50 mM sodium fluoride, 1 mM sodium orthovanadate, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 5 mg/ml aprotinin, 1 mg/ml pepstatin A, 2 mg/ml leupeptin).
The cells were lysed and the insoluble material was removed by centrifugation at 15 000 g for 20 min at 41C. For immunoprecipitation, 500 mg of protein lysate was incubated with antibody overnight at 41C. Protein A-agarose for the polyclonal antibodies or Protein G-Sepharose 4 FF for the monoclonal antibodies was added for an additional 1 h at 41C. Agarose pellets were washed three times in the above lysis buffer and bound proteins were removed by boiling in SDS electrophoresis sample buffer. Lysates or immunoprecipitates were separated on 4-12 or 7% SDS-PAGE as indicated and transferred electrophoretically to polyvinylidene fluoride membrane (Millipore, Bedford, MA, USA). For immunoblotting, blocking buffer was TBS-T (0.15 M NaCl, 0.1% Tween 20, 50 mM Tris, pH 8.0) with 3% bovine serum albumin (BSA). Secondary antibody was goat anti-mouse immunoglobulin conjugated to horseradish peroxidase and antibody binding was detected using ECL. When needed, blots were stripped in buffer (2% SDS, 0.1 M 2-mercaptoethanol, 62.5 mM Tris, pH 6.8) at 701C for 80 min and rinsed extensively in TBS-T before being reprobed.
Analysis of E-cadherin levels in T-47D xenograft tumors in vivo
Ovariectomized female athymic nude mice (N ¼ 12, 6-8 weeks of age) with s.c. implants of slow-release 17 b-estradiol pellets (1.7 mg, 30-day release; Innovative Research of America, Sarasota, FL, USA) were inoculated s.c. with human T-47D cells (5 Â 10 6 cells suspended in 200 ml of 50% Matrigel (BD Biosciences, Bedford, MA, USA) and 50% RPMI-1640 (Biofluids, Rockville, MD, USA) into each of two dorsolateral sites. After 14 days, the nine mice with most consistent paired tumors of approximately 4 mm 3 each were selected and randomly distributed into three groups. The mice were treated daily with PRL (s.c. 5 mg/g body weight; Nevalainen et al., 2002) for 0, 2, or 4 days in the continued presence of estrogen implants. At 3 h after final injections, mice were euthanized and the two tumors were harvested from each mouse. Each tumor was split into two, and one-half was snap-frozen on dry ice for analysis of E-cadherin levels in tumor extracts or by immunohistochemistry of frozen sections, and the other half was fixed in 10% buffered formalin for paraffin embedding and immunohistochemical analysis of Stat5 activation or Ecadherin. Immunohistochemical detection of nuclear-localized, tyrosine-phosphorylated Stat5 was performed using monoclonal antibody AX1 as described previously . Immunohistochemical detection of E-cadherin was performed by diaminobenzidine-based staining of paraffinembedded sections using monoclonal antibody (DakoCytomation). For bright field imaging, an Olympus Vanox Microscope equipped with a Zeiss Â 25/0.8 NA objective lens was used. For fluorescence imaging, a Nikon Eclipse E600 fluorescence microscope was used. Proteins were extracted from frozen tumors by homogenization in T-PER reagent (Pierce) and were analysed by Western blotting using specific E-cadherin monoclonal antibody.
Immunofluorescence staining of E-cadherin and b-catenin
Immunofluorescence measurements were performed as described (Zhang et al., 1999) . Briefly, cells were grown to subconfluence on glass coverslips in six-well tissue plates and were either mock infected or infected with adenovirus carrying Wt-Stat5a, Wt-Stat3, Wt-Jak2, Dn-Stat5, Dn-Stat3, or DnJak2 as indicated for 90 min. For all adenoviral infections, multiplicity of infection (m.o.i.) 25 was used, except for Wtand Dn-Jak2 (m.o.i. 10). After 16 h, cells were treated with or without 20 nM PRL for 18 h. Adherent cells on coverslips were washed once with PBS (10 mM sodium phosphate, pH 7.4, 140 mM NaCl, 3 mM KCl), fixed in 4% paraformaldehyde in PBS for 15 min, and then permeabilized by 0.5% Triton X-100 in PBS for another 15 min. Nonspecific binding was prevented by incubation in PBS containing 5% BSA for 30 min. Cells were then incubated for 2 h with mouse monoclonal antibodies to E-cadherin or b-catenin, at a final concentration of 800 ng/ml in PBS containing 5% BSA. Coverslips were washed to remove unbound antibodies and further incubated for 30 min with FITC-conjugated goat anti-mouse secondary antibody (Vector Laboratories) and DNA was stained with propidium iodide. After final washing, coverslips were mounted using the Prolong antifade kit (Molecular Probes, Eugene, OR, USA) and cells were visualized and photographed under a Nikon Eclipse E600 fluorescence microscope at Â 200 magnification for E-cadherin and Â 400 magnification for b-catenin.
Tyrosine phosphorylation of b-catenin and EGF-R T-47D cells were plated at a density of 4 Â 10 4 cells in 75-cm 2 dishes and cultured in DMEM containing 10% FBS for 48 h. The resulting subconfluent cells were further cultured for 24 h in DMEM containing 2% FBS, treated with or without 20 nM PRL for up to 48 h as indicated. Immediately before collection, cells were exposed to 8.0 nM EGF for 30 min. After washing with ice-cold PBS, cells were lysed in lysis buffer for 30 min on ice and insoluble components were removed by centrifugation at 15 000 g for 20 min at 41C. b-Catenin and EGF-R were immunoprecipitated using monoclonal anti-b-catenin antibody or polyclonal anti-EGF-R, respectively, subjected to 7% SDS-PAGE, and immunoblotted with anti-phosphotyrosine monoclonal antibody, 4G10. After stripping, the membranes were reblotted for b-catenin protein or EGF-R protein.
Analysis of homotypic clustering of breast cancer cells on Matrigel
T-47D or BT-20 cells were seeded on glass coverslips coated with 0.5 ml of Matrigel (5 mg/ml) in six-well plates for 48 h. Cells were either mock infected or infected with adenovirus carrying Wt-Stat5a or Dn-Stat5 at m.o.i. 25 for 90 min. BT-20 cells were either mock infected or infected with adenovirus carrying Wt-Jak2, Wt-Stat5a, Dn-Stat5, or a combination of Wt-Jak2 and Wt-Stat5 at m.o.i. 25 for Wt-Stat5 or Dn-Stat5 and at m.o.i. 5 for Wt-Jak2 for 90 min. The resulting subconfluent cultures were further incubated for 24 h in DMEM containing 2% FBS and were then treated with medium alone (control) or 20 nM PRL. After 24-72 h of incubation at 371C, cells were fixed as indicated in 4% paraformaldehyde in PBS for 15 min. Cells were washed twice with PBS and cell morphological alterations were analysed using phase contrast microscopy (Nikon Stereoscope, Chuoku, Japan) at Â 200 magnification. BT-20 cell clusters induced by Wt-Jak2 plus Wt-Stat5 were subjected to further analysis for E-cadherin localization by immunohistochemistry, using specific E-cadherin monoclonal antibody, visualized, and analysed under Vanox Microscope equipped with a Zeiss Â 25/0.8 NA objective lens.
Assays of cell invasion and cell mobility
The ability of breast cancer cells to migrate (mobility) was analysed using a Boyden chamber (Transwell filters unit, pore size 8 mm; Becton Dickinson & Co., Bedford, MA, USA) according to standard protocols (Albini et al., 1987) . For the invasion assay, Transwell filter units were used that had been precoated with a barrier of extracellular matrix, Matrigel (50 mm). In both assays, fibroblast conditioned medium, which was obtained by a 24 h incubation of NIH-3T3 cells with 50 mg/ml ascorbic acid in serum-free DMEM, was placed in the lower chamber as a chemoattractant. Cells were either mock infected or infected with adenovirus carrying Wt-Stat5a or Dn-Stat5 at m.o.i. 25 for 90 min and treated with or without 20 nM PRL for 18 h as described above. Single-cell suspensions were obtained by treatment with PBS containing 5 mM EDTA, washed, and placed at 10 5 cells per well into the upper chamber in 0.5 ml DMEM containing 0.1% BSA in the presence or absence of 20 nM PRL for 24 h. Cells that had not penetrated the filter were wiped out with cotton swabs, and cells that had migrated to the lower surface of the filter were stained with 0.5% crystal violet, photographed, and quantified by dissolving stained cells in 10% acetic acid and measuring optical density at 560 nm. The data represent the average of three independent experiments with the s.d. indicated.
Zymography for gelatinolytic activity
Secreted metalloproteinase (MMP) activities were detected and characterized by zymography as previously described (Yasumitsu et al., 1992) . Conditioned media were obtained after a 30 h incubation period of cells that had either been mock infected or infected with adenovirus carrying Wt-Stat5a or Dn-Stat5 at m.o.i. 25 for 90 min and treated with or without 20 nM PRL during the 30 h period. No detectable change in cell number was observed during this brief treatment period. MMPs were extracted using Gelatin Sepharose 4B beads Stat5 inhibits breast cancer cell invasion AS Sultan et al (Amersham Pharmacia Biotech, Piscataway, NJ, USA) that had been washed three times with equilibration buffer, pH 7.5 (50 mM Tris, 150 mM NaCl, 5 mM CaCl 2 , 0.02% Tween 20, 0.07% Brij 35, 10 mM EDTA). A 100 ml portion of equilibrated Gelatin Sepharose beads was added to 4 ml of conditioned medium and samples were placed on an end-over-end shaker overnight at 41C to allow the binding of gelatinases to the Gelatin Sepharose. Nonspecific binding was removed by washing Gelatin Sepharose beads with the equilibration buffer containing 200 mM NaCl, and MMPs were eluted with 20 ml of nonreducing 2 Â Tris-glycine-SDS sample buffer. Samples were subjected to a 10% polyacrylamide gel impregnated with gelatin (1 mg/ml). Electrophoresis was performed under nonreducing conditions at 125 V for 2 h at 41C. After electrophoresis, gels were rinsed twice in 2.5% (w/v) Triton X-100 and three times in double-distilled H 2 O at room temperature, incubated at 371C for 48 h in enzyme buffer (50 nM Tris-HCl, pH 7.8, 5 mM CaCl 2 , 0.15 M NaCl, 1% (w/v) Triton X-100) and, then stained with a solution containing 0.1% (w/v) Coomassie brilliant blue R-250, 12.5% (v/v) ethanol, and 7.5% (v/v) acetic acid. The gels were destained in 45% methanol and 10% acetic acid in H 2 O. Gelatinolytic enzymes were detected as transparent bands after Coomassie blue staining.
